This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

QIAGEN's Ingenuity® Variant Analysis™ Selected For Translational Genomics By Icahn School Of Medicine At Mount Sinai

Stocks in this article: QGEN

NEW YORK and REDWOOD CITY, California and HILDEN, Germany, October 22, 2013 /PRNewswire/ --

  • Mount Sinai collaboration with QIAGEN Center of Excellence in Biological Interpretation demonstrates translational value of high-quality analysis of gene variants in rare diseases
  • Accuracy and ease of use for clinical and labora to ry geneticists and other medical professionals are cited in selection of genomic analysis solutions from QIAGEN
  • Medical school also will use Ingenuity Variant Analysis  to  train next generation of medical professionals in genome interpretation

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai in New York City have adopted the Ingenuity ® Variant Analysis™ solution for research and translational genomics applications related to characterizing and identifying rare diseases. Ingenuity Variant Analysis will also serve as the genome interpretation platform for training at the Icahn School of Medicine at Mount Sinai that gives researchers and future physicians the opportunity to sequence and perform detailed analyses of their own genomes.

QIAGEN's Ingenuity Variant Analysis is a web-based software application that quickly filters genetic variants to identify those most likely to cause disease, providing researchers a powerful platform for efficiently evaluating data generated by high-throughput next-generation sequencing (NGS) technologies. It is built on the Ingenuity Knowledge Base, the most extensive manually curated, integrated repository of genomic information, scientific literature, and public databases.

The Genetic Testing Lab and Icahn Institute chose Ingenuity Variant Analysis because of its accuracy and ease of use for clinical and laboratory geneticists and other professionals investigating links between known mutations and rare diseases, according to Eric Schadt, Ph.D., Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.

"In our efforts to provide answers to families who may have spent years on a frustrating and painful diagnostic odyssey, this ability to dramatically accelerate the process of getting to a medically relevant insight is invaluable," Dr. Schadt said. "Our mission is to bring to bear as much information as possible to help each patient. The combination of Ingenuity Variant Analysis and the Ingenuity Knowledge Base is an essential part of achieving that goal."

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs